{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P17813",
      "entity_text" : "end",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:208898",
      "entity_text" : "dronedarone",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "A Placebo Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg bid for the Prevention of Cardiovascular Hospitalization or Death from Any Cause in Patients with Atrial Fibrillation / Atrial Flutter (ATHENA) was conducted to determine if dronedarone could decrease the composite end point of cardiovascular hospitalizations or death in patients with atrial fibrillation.",
  "reading_complete" : "2020-08-05T22:09:43Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-05T22:07:19Z",
  "trigger" : "decrease",
  "evidence" : [ "dronedarone could decrease the composite end" ],
  "pmc_id" : "2963922",
  "score" : 0
}